http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Han Sungpil,Choi Hee Youn,Kim Yo Han,Choi SeungChan,Kim Seokuee,Nam Ji Yeon,Kim Bongtae,Song Geun Seog,Lim Hyeong-Seok,Bae Kyun-Seop 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.1
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough in healthy subjects. Methods: In a randomized, open-label, single-dose, balanced incomplete block crossover study, 24 healthy male volunteers were enrolled and randomized to receive oral tegoprazan (50, 100, or 200 mg) or dexlansoprazole (60 mg) during each of two administration periods, separated by a 7- to 10-day washout period. Blood samples were collected for pharmacokinetic parameter analysis; gastric monitoring was performed for pharmacodynamic parameter evaluation. Results: All 24 subjects completed the study. Average maximum plasma concentration, area under the plasma concentration–time curve, and mean time with gastric pH >4 and pH >6 for tegoprazan demonstrated dose-dependent incremental increases. All the tegoprazan groups reached mean pH ≥4 within 2 hours, whereas the dexlansoprazole group required 7 hours after drug administration. Based on pharmacodynamic parameters up to 12 hours after evening dosing, 50, 100, and 200 mg of tegoprazan presented a stronger acid-suppressive effect than 60 mg of dexlansoprazole. Moreover, the dexlansoprazole group presented a comparable acid-suppressive effect with the tegoprazan groups 12 hours after dosing. Conclusions: All the tegoprazan groups demonstrated a significantly faster onset of gastric pH increase and longer holding times above pH >4 and pH >6 up to 12 hours after evening dosing than the dexlansoprazole group.
한희준 ( Heejun Han ),최성필 ( Sungpil Choi ) 한국정보처리학회 2018 한국정보처리학회 학술대회논문집 Vol.25 No.1
방대한 정보를 사용자에게 제공하기 위해 검색 엔진은 다양한 알고리즘을 통해 사용자마다의 최적화된 정보를 구성한다. 과제, 논문, 특허, 연구보고서 등 과학기술정보를 서비스 하는 주체 역시 나름의 검색 알고리즘으로 정보를 제공하지만, 질의어와 문서간의 적합도만을 측정하여 검색 결과를 제시할뿐 사용자의 관심 분야나 요구를 반영하지 않고 있다. 특히 관심 분야에 적합한 과학기술정보를 사용자가 접근하기 쉽게 제공하는 것은 매우 중요하다. 본 논문에서는 사용자 관심분야를 서비스 이용행태로부터 결정하여 이를 과학기술정보 개인화에 반영하는 서비스에 대해 제안하였다. 이를 위해 실시간 관심분야 추적, 관심 태그 클라우드 제공, 관심분야 기반 추천정보 제공, 검색 결과 개인화 네 가지 기능으로 구성된 과학기술정보 개인화 서비스를 설계하고 구현하였다.
Development of R packages: ‘NonCompart’ and ‘ncar’ for noncompartmental analysis (NCA)
Hyungsub Kim,Sungpil Han,조용순,Seok-Kyu Yoon,Kyun-Seop Bae 대한임상약리학회 2018 Translational and Clinical Pharmacology Vol.26 No.1
Noncompartmental analysis (NCA) is a primary analytical approach for pharmacokinetic studies,and its parameters act as decision criteria in bioequivalent studies. Currently, NCA is usuallycarried out by commercial softwares such as WinNonlin®. In this article, we introduce our newlydevelopedtwo R packages, NonCompart (NonCompartmental analysis for pharmacokinetic data)and ncar (NonCompartmental Analysis for pharmacokinetic Report), which can perform NCAand produce complete NCA reports in both pdf and rtf formats. These packages are compatiblewith CDISC (Clinical Data Interchange Standards Consortium) standard as well. We demonstratehow the results of WinNonlin® are reproduced and how NCA reports can be obtained. With these Rpackages, we aimed to help researchers carry out NCA and utilize the output for early stages of drugdevelopment process. These R packages are freely available for download from the CRAN repository.
Purification and Characterization of Protein Carboxyl O-Methyltransferase from Porcine Spleen
Hong,Sungyoul,Yoon,Sungpil,Son,Minsik,Han,Jeung-Whan,Lee,Hyang Woo The Korea Science and Technology Center 1997 BMB Reports Vol.30 No.6
We purified a protein carboxyl O-methyltransferase (protein methylase Ⅱ) from porcine spleen to homogeneity. The molecular weight of the porcine spleen protein methylase Ⅱ (ps-PM Ⅱ) was estimated to be 27,500 daltons on SDS-PAGE. Amino acid sequence of N-terminal 28 residues for ps-PM Ⅱ was identified. Amino-terminal three amino acid residues of ps-PM Ⅱ were deleted when compared to those of other protein carboxyl methytransferase. S-Adenosyl-L-homocysteine competitively inhibits ps-PM Ⅱ with a K? value of 1.63×10? M. Myelin basic protein exhibited the highest methyl-accepting capacity among the proteins tested.
Yunjung Hong,Sangil Jeon,Suein Choi,Sungpil Han,Maria Park,Seunghoon Han 대한생리학회-대한약리학회 2021 The Korean Journal of Physiology & Pharmacology Vol.25 No.6
Fixed-dose combinations development requires pharmacokinetic drugdrug interaction (DDI) studies between active ingredients. For some drugs, pharmacokinetic properties such as long half-life or delayed distribution, make it difficult to conduct such clinical trials and to estimate the exact magnitude of DDI. In this study, the conventional (non-compartmental analysis and bioequivalence [BE]) and modelbased analyses were compared for their performance to evaluate DDI using amlodipine as an example. Raw data without DDI or simulated data using pharmacokinetic models were compared to the data obtained after concomitant administration. Regardless of the methodology, all the results fell within the classical BE limit. It was shown that the model-based approach may be valid as the conventional approach and reduce the possibility of DDI overestimation. Several advantages (i.e., quantitative changes in parameters and precision of confidence interval) of the model-based approach were demonstrated, and possible application methods were proposed. Therefore, it is expected that the model-based analysis is appropriately utilized according to the situation and purpose.